Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technol
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ), a biotechnology ... in the areas of dermatology and ophthalmology today announced ... quarter ended June 30, 2015 on Wednesday, August 12, ... A live audio webcast will begin ... under the "Investors" section of the Company,s website, ...
(Date:7/29/2015)... July 29, 2015   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" ... quarter 2015 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:7/29/2015)... Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that ... District of West Virginia (W.Va) pushed ... to start in November. The first trial that was set ... and now it involves 39 women, and the trial has ... an article in Reuters. The alterations were made after data ...
Breaking Medicine Technology:RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 2RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 3BioLife Solutions to Report Second Quarter 2015 Financial Results and Provide Business Update on August 6, 2015 2Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3
... 28 BioCis Pharma Ltd., a,privately-held drug development ... Phase I clinical testing of ProtoCure(TM) intravesical,instillation solution, ... is based on a new mechanism of action ... cancer growth and proliferation,locally. , ...
... a leader in the field of human gene therapy,announced ... Drug,Designation to AMT,s gene therapy product AMT-021 for the ... Orphan Drug Designation for AIP entitles AMT to ... AMT-021 if this,product candidate is the first new drug ...
Cached Medicine Technology:BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug 2AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria 2AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria 3
(Date:7/29/2015)... Baltimore, MD (PRWEB) , ... July 29, 2015 , ... ... to Get Checked for Skin Cancer ," discussed the importance of having regular skin ... if a person has excessive exposure to ultraviolet rays. When caught early, skin cancer ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order ... with autism, Little City took a proactive stance and began planning the Children’s Village ... grant provides valuable support to building the third home. , “We are very pleased ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Since the late 1970s, Dr. Cottrell has been making predictions about the economy, ... Earth, documents many of these prognostications. He warns that extreme weather conditions and ...
(Date:7/29/2015)... North Carolina (PRWEB) , ... July 29, 2015 ... ... MetLife, Inc ., a global provider of life insurance, annuities, employee benefits ... Team Challenge North Carolina inclusive sporting event taking place in Charlotte, North ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... is seeking funding for a study on the potentially lifesaving impact of removing ... today . , The research proposal is based on a successful pilot ...
Breaking Medicine News(10 mins):Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3
... good for heart health, at least among men, a ... researcher Robert Gramling, M.D., D.Sc., found that men who ... actually experienced a three times lower incidence of death ... not support the same conclusion among women. One possible ...
... Australian first, scientists at Sydney,s Centenary Institute have mapped ... has the potential to turn the way we discover ... time for new treatments. , "These membrane proteins are ... an increased,understanding of them is vital for future drug ...
... Theoretical Bioinformatics at the German Cancer Research Center (Deutsches ... how cells decide whether or not to migrate. Using ... molecular targets within a cell that have to be ... direction. This method may help to develop new treatments ...
... YORK and PARSIPPANY, N.J., July 14 Healthfirst ... a free online service,for electronic claims submissions. This ... medical providers to do business with the health ... faster exchange of,information, higher acceptance rates and quicker ...
... announced the appointment of Gregory Ciottone,MD to the position of Chief ... ... Company., LONGMONT, Colo., July 14 ... Ciottone, MD,to the position of Chief Medical Officer. Dr. Ciottone will ...
... Combat Lifesaver ... ... the summer of 2005, the,U.S. Army approached Recon Mountaineer(R) LLC ... the Combat Lifesaver program, and,at gaining their approval, the TC3(R) ...
Cached Medicine News:Health News:Positive thinking is prescription for the heart 2Health News:Discovery first step to new therapies 2Health News:Cellular decision on the computer 2Health News:Healthfirst and MD On-Line Partner to Streamline Claims Processing 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 3Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 4Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 5Health News:Creator of Recon Moutaineer's Tactical Combat Casualty Care Bag Praises Combat Lifesavers 2
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl....
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The Proteineer suite integrates powerful mass spectrometers with robotics and bioinformatics to deliver maximum productivity in high-throughput proteomics....
The ProteomeLab PA 800 resolves and quantifies proteins by their isoelectric point and molecular weight, generates high-resolution peptide maps and carbohydrate profiles and provides front-end separa...
Medicine Products: